Results 161 to 170 of about 3,100,266 (306)

Selective elimination of quiescent cancer cells by dequalinium chloride via ROS‐mediated ferroptosis

FEBS Open Bio, EarlyView.
Dequalinium chloride (DQ) selectively eliminates quiescent cancer cells (QCCs) by amplifying mitochondrial ROS. QCCs exhibit elevated basal ROS and limited redox‐buffering capacity, making them vulnerable to further ROS increases. DQ‐induced ROS exceeds the tolerance threshold, triggering lipid peroxidation and ferroptosis, whereas proliferating cells ...
Kotaro Miyamoto, Shiori Sakai, Minori Endo, Terigele, Mizuho Niibori, Taiki Morita, Yu Goto, Arisa Yoshida, Tomohiro Tanaka, Ning Lin, Takahiro Kuchimaru, Hiroyuki Nakamura, Masahiro Inoue, Shinae Kizaka‐Kondoh, Tetsuya Kadonosono   +14 more
wiley   +1 more source

Stem cell-based tactics in the remodeling and treatment of intestinal diseases. [PDF]

Stem Cell Res Ther
Ren Y, Zhang S, Wang J, Wang Y, Xu M, Zhang L, Ge K, Chu Y, Zhang L.   +8 more
europepmc   +1 more source

A nationwide student survey on biochemistry learning resources in Italy

FEBS Open Bio, EarlyView.
We conducted a survey among Italian university students to investigate their preferred study materials for biochemistry. We then analyzed the collected data to identify these materials. This information may be valuable to the Biochemistry educational community. The graphical abstract was created with Claude (Opus 5.5; Anthropic, 2026).
Anna Marabotti, Ivano Eberini, Maria Luisa Genova, Francesca Mensitieri, Francesco Malatesta   +4 more
wiley   +1 more source

Vitamin D and Intestinal Diseases: Impact on Intestinal Immunity and Gut Barrier Function. [PDF]

Diseases
Shorabaev E, Sadanov A, Baimakhanova B, Orasymbet S, Ratnikova I, Kerimzhanova B, Assilova Z, Datkhayeva Z, Turgumbayeva A.   +8 more
europepmc   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

FEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao, Leonie Meyer, Madita Braun, Katharina Otte, Celine Bitter, Maite Pawlik, Hartmann Raifer, Frederik Helmprobst, Axel Pagenstecher, Hans Urban, Michael C. Burger, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jarmila Jedelská, Shamim Bagheri, Behrooz H. Yousefi, Pietro Di Fazio, Markus Luster, Andreas H. Mahnken, Andreas Neubauer, Andreas Burchert, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch   +23 more
wiley   +1 more source

FOXP3 Stability-Adaptation Paradox: Reshaping Treg-Based Therapies for Intestinal Diseases. [PDF]

Int J Biol Sci
Ren Y, Liu X, Wang B, Yin H, Zhao J, Xin S, Wang H, Zhang Y, Liu X, Liu J, Hua R, Tian X, Bian Y, Gu S, Zhang H, Wei T, Gao L, Lu X, Shang H, Gao H, Xu J.   +20 more
europepmc   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Current Status of Intestinal Stem Cell Research: Mechanisms, Intestinal Diseases, and Organoid Development. [PDF]

Cells
Li Y, Lai R, He Y, Cheng K, Cheng L, Yi J, Li Y, Zhou S.   +7 more
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Advances of oral micro- and nanomedicines for modulating intestinal barriers in the treatment of intestinal diseases. [PDF]

Acta Pharm Sin B
Yang M, Zhu Y, Li Q, Deng Z, Xu C, Wei X, Ma Y, Ding C, Zhang M, Ma S, Zhang M.   +10 more
europepmc   +1 more source